MZT2B and non-small cell lung carcinoma: Together, MZT2B is consistently upregulated in NSCLC that correlates with adverse clinicopathological features and poor prognosis and critically regulates mitochondrial function and promotes NSCLC progression, in part, by promoting COX5B expression.